Compare Nuscale Power Corporation (SMR) vs 10X Genomics Inc (TXG) Price & Performance

SMR stock trades at $11.18, up 15.32% in the last 24 hours, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with a negative net income margin of -3,888.7% and a high price-to-sales ratio of 272.59. Recent news highlights its cash position and potential in small modular reactors for AI energy demand.

Outlook is speculative with high growth potential from nuclear energy trends but significant execution risks. Analysts are divided, with a 50% buy rating and $11.25 consensus target. Key risks include cash burn, lack of profitability, and project delays, requiring cautious investor consideration.

TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.

Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.